Literature DB >> 17190027

The relationships among depression, pain, and masticatory functioning in temporomandibular disorder patients.

Robert J Gatchel1, Anna W Stowell, Peter Buschang.   

Abstract

AIMS: To evaluate the effect of comorbid depression and pain on an early biopsychosocial intervention for acute temporomandibular disorder (TMD) patients.
METHODS: Depressed (either current or lifetime; n=32) or nondepressed (n=31) acute TMD patients received a biopsychosocial intervention, and were evaluated at preintervention and again 12 months postintervention by Characteristic Pain Intensity, the Beck Depression Inventory, and a masticatory function test.
RESULTS: Findings revealed that both depressed and nondepressed patients reported comparable pain decreases at 12 months postintervention. Moreover, there were no significant differences between patient groups in masticatory function.
CONCLUSION: With appropriate early biopsychosocial intervention, acute TMD patients, regardless of the presence or absence of vulnerability to depression symptomatology, can be effectively treated.

Entities:  

Mesh:

Year:  2006        PMID: 17190027

Source DB:  PubMed          Journal:  J Orofac Pain        ISSN: 1064-6655


  3 in total

1.  The prevalence of comorbid symptoms of central sensitization syndrome among three different groups of temporomandibular disorder patients.

Authors:  Kara M Lorduy; Angela Liegey-Dougall; Robbie Haggard; Celeste N Sanders; Robert J Gatchel
Journal:  Pain Pract       Date:  2013-01-22       Impact factor: 3.183

2.  Temporomandibular pain and depression in adolescents--a case-control study.

Authors:  C Hirsch; J C Türp
Journal:  Clin Oral Investig       Date:  2009-04-01       Impact factor: 3.573

3.  Smiling, Yawning, Jaw Functional Limitations and Oral Behaviors With Respect to General Health Status in Patients With Temporomandibular Disorder-Myofascial Pain With Referral.

Authors:  Joanna Kuć; Krzysztof Dariusz Szarejko; Maria Gołȩbiewska
Journal:  Front Neurol       Date:  2021-05-24       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.